Get started
AEGIRBIO ABAEGIRBIO ABAEGIRBIO AB

AEGIRBIO AB

No trades
See on Supercharts
Overview
Financials
News Ideas Technicals

AEGIR fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

AegirBio AB engages in the development and commercialization of drug monitoring tests. Its products include Viraspec COVID-19 Saliva Test and moNATor. The company was founded on September 26, 2019 and is headquartered in Lund, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

AEGIR does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company